September 2000
Science Teacher;Sep2000, Vol. 67 Issue 6, p17
Academic Journal
Reports on the findings of a study on the use of gene therapy to treat Duchenne muscular dystrophy. Difficulty of developing gene therapy for the condition; Causes of the disease.


Related Articles

  • Gene Therapy for Muscular Dystrophies: Current Status and Future Prospects. Takeda, S.; Miyagoe-Suzuki, Y. // BioDrugs;2001, Vol. 15 Issue 10, p635 

    Since the identification in 1987 of the gene for Duchenne muscular dystrophy (DMD), research on the molecular pathogenesis of muscular dystrophy has progressed extensively. In particular, discovery of the DMD gene product, dystrophin, led to the identification of dystrophin-associated proteins...

  • A novel miniDys_eGFP fusion gene for developing cell_based therapies of Duchenne muscular dystrophy  // Molecular Therapy;May2004 Supplement 1, Vol. 9, p93 

    An abstract of the article "A Novel MiniDys-eGFP Fusion Gene for Developing Cell-Based Therapies of Duchenne Muscular Dystrophy," by Sheng Li, En Kimura, Leonard Meuse, Xin Ye, Brent Fall, Steven D. Hauschka, John Faulkner and Jeffrey S. Chamberlain is presented.

  • Mini-gene injection prevents muscle-wasting disease. Webb, Jeremy // New Scientist;8/28/93, Vol. 139 Issue 1888, p8 

    Reports on the development of a miniature artificial dystrophin gene designed for viruses used to shuttle the gene into cells in gene therapy for sufferers of Duchenne muscular dystrophy (DMD). Description of DMD; Jeffery Chamberlain and the University of Michigan Medical School; Elimination of...

  • Isolating the gene for Duchenne muscular dystrophy. Harper, Peter S. // British Medical Journal (Clinical Research Edition);9/27/1986, Vol. 293 Issue 6550, p773 

    Examines the isolation of genes for Duchenne muscular dystrophy. DNA techniques in the identification of a gene; Variations in DNA sequence; Combination of DNA analysis with the approach of creatine kinase testing.

  • Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein–Barr virus (EBV)-based mini-chromosome vectors in mdx mice. Tsukamoto, H; Wells, D J; Brown, S C; Serpente, P; Strong, P N; Drew, J; Inui, K; Okada, S; Dickson, G // Gene Therapy;Jul99, Vol. 6 Issue 7, p1331 

    Gene transfer by direct intramuscular injection of naked plasmid DNA has been shown to be a safe, simple but relatively inefficient method for gene delivery in vivo. Eukaryotic plasmid expression vectors incorporating the Epstein–Barr virus (EBV) origin of replication (oriP) and EBNA1...

  • Cut the nonsense.  // New Scientist;4/28/2007, Vol. 194 Issue 2601, p16 

    The author discusses the use of medication to overcome gene mutations that cause diseases such as cystic fibrosis and Duchenne muscular dystrophy. Details related to study results supporting the use of the antibiotic gentamicin and a new drug that restored muscle function in a mouse model and...

  • In brief.  // Nature Reviews Genetics;Oct2011, Vol. 12 Issue 10, p668 

    The article offers information on various research related to genetics including a study on the relation of mobile retrotransposon on the human genomic variation, the gene therapy for Duchenne muscular dystrophy (DMD) using human artificial chromosomes (HAC,) and on haploid embryonic stem cells...

  • Prosensa, GSK: $25M Up Front for DMD Work.  // Bioworld Week;10/19/2009, Vol. 17 Issue 42, p4 

    The article reports that Prosensa Therapeutics BV of Leiden, Netherlands obtains an up-front payment of 16 million pounds in a RNA-based drug development partnership with GlaxoSmithKline (GSK) PLC. in the X-linked Duchenne muscular disorder (DMD). It cites that GSK will give additional fund for...

  • Rescue of a Dystrophin-like Protein by Exon Skipping In Vivo Restores GABAA-receptor Clustering in the Hippocampus of the mdx Mouse. Vaillend, Cyrille; Perronnet, Caroline; Ros, Carine; Gruszczynski, Carole; Goyenvalle, Aurélie; Laroche, Serge; Danos, Olivier; Garcia, Luis; Peltekian, Elise // Molecular Therapy;Sep2010, Vol. 18 Issue 9, p1683 

    Dystrophin, the cytoskeletal protein whose defect is responsible for Duchenne muscular dystrophy (DMD), is normally expressed in both muscles and brain. Genetic loss of brain dystrophin in the mdx mouse model of DMD reduces the capacity for type A γ-aminobutyric acid (GABAA)-receptor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics